SYNERGY BETWEEN BETA-1, 3-GLUCAN AND PRAZIQUANTEL IN THE TREATMENT OF EXPERIMENTAL CHRONIC SCHISTOSOMIASIS MANSONI
ELGENDY, D., OTHMAN, A., EL-GUINDY, D., SOLIMAN, N., ELMEHY, D. (2020). SYNERGY BETWEEN BETA-1, 3-GLUCAN AND PRAZIQUANTEL IN THE TREATMENT OF EXPERIMENTAL CHRONIC SCHISTOSOMIASIS MANSONI. EKB Journal Management System, 50(3), 565-574. doi: 10.21608/jesp.2020.131088
DINA I. ELGENDY; AHMAD A. OTHMAN; DINA M. EL-GUINDY; NEMA A. SOLIMAN; DALIA A. ELMEHY. "SYNERGY BETWEEN BETA-1, 3-GLUCAN AND PRAZIQUANTEL IN THE TREATMENT OF EXPERIMENTAL CHRONIC SCHISTOSOMIASIS MANSONI". EKB Journal Management System, 50, 3, 2020, 565-574. doi: 10.21608/jesp.2020.131088
ELGENDY, D., OTHMAN, A., EL-GUINDY, D., SOLIMAN, N., ELMEHY, D. (2020). 'SYNERGY BETWEEN BETA-1, 3-GLUCAN AND PRAZIQUANTEL IN THE TREATMENT OF EXPERIMENTAL CHRONIC SCHISTOSOMIASIS MANSONI', EKB Journal Management System, 50(3), pp. 565-574. doi: 10.21608/jesp.2020.131088
ELGENDY, D., OTHMAN, A., EL-GUINDY, D., SOLIMAN, N., ELMEHY, D. SYNERGY BETWEEN BETA-1, 3-GLUCAN AND PRAZIQUANTEL IN THE TREATMENT OF EXPERIMENTAL CHRONIC SCHISTOSOMIASIS MANSONI. EKB Journal Management System, 2020; 50(3): 565-574. doi: 10.21608/jesp.2020.131088

SYNERGY BETWEEN BETA-1, 3-GLUCAN AND PRAZIQUANTEL IN THE TREATMENT OF EXPERIMENTAL CHRONIC SCHISTOSOMIASIS MANSONI

Journal of the Egyptian Society of Parasitology
Article 12, Volume 50, Issue 3, December 2020, Page 565-574  XML PDF (1.52 MB)
Document Type: Original Article
DOI: 10.21608/jesp.2020.131088
View on SCiNiTO View on SCiNiTO
Authors
DINA I. ELGENDY1; AHMAD A. OTHMAN1; DINA M. EL-GUINDY2; NEMA A. SOLIMAN3; DALIA A. ELMEHY1
1Department of Medical Parasitology
2Department of Pathology
3Department of Medical Biochemistry
Abstract
Praziquantel can develop resistance and cannot counteract schistosomiasis pathology. β-glucan
was used as an immunomodulator for innate and acquired immunity. This study evaluated the
effects of β-glucan either alone or with PZQ on chronic Schistosoma mansoni infection. Mice
were divided into five groups: uninfected control, infected untreated, PZQ treated, β-glucan
treated and combined treatment groups. Treatment started at the end of 8th week P.I. Parasitological,
histopathological, immunohistochemical (α-SMA) studies and biochemical assays (Myeloperoxidase
activity, NO, TNF-α, INF-γ, IL-13 & hydroxyproline) in liver tissues were done.
Combination of β-glucan and PZQ therapy resulted in significant decrease in adults count, hepatic
egg loads, granuloma number and diameter as well as significant improvement of hepatic
pathology and reduction of hepatic fibrosis.
Keywords
Schistosoma mansoni; β-1; 3-glucan; NO; Alpha smooth muscle actin; TNF-α; INF- γ; Hepatic fibrosis
Statistics
Article View: 217
PDF Download: 176